FDA Issues Boxed Warning for CYP2C19-Linked Poor Metabolism of Plavix
March 17, 2010
FDA Issues Boxed Warning for CYP2C19-Linked Poor Metabolism of Plavix
The boxed warning for Plavix's label alerts doctors that genetic tests are available to establish patients' CYP2C19 status. However, the FDA leaves it up to physicians to decide whether to wait for genetic testing results or put patients on an alternative treatment.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 2, 2011 / Pharmacogenomics Reporter - Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter - New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 1, 2010 / Pharmacogenomics Reporter - Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
March 17, 2010 / Pharmacogenomics Reporter